Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other Operating Expenses (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Other Operating Expenses for 4 consecutive years, with $26.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $26.4 million in Q3 2025 year-over-year; TTM through Dec 2025 was $26.4 million, a 15784.94% increase, with the full-year FY2011 number at $17.3 million, down 82.28% from a year prior.
  • Other Operating Expenses was $26.4 million for Q3 2025 at Lexicon Pharmaceuticals, up from $166000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $26.4 million in Q3 2025 to a low of $166000.0 in Q2 2024.